Laziros

Azacitidine, the active ingredient in Laziros, is a DNA methyltransferase inhibitor presented as a sterile powder for reconstitution for subcutaneous injection. It is indicated for the treatment of myelodysplastic syndromes and acute myeloid leukemia in adult patients requiring disease‑modifying therapy.

GNH USA supplies Laziros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacy chains worldwide, ensuring quality‑assured product handling, regulatory compliance, and dedicated logistics and technical support for safe efficient delivery across global markets.

Azacitidine is used in hematologic malignancies that involve abnormal DNA methylation. - Myelodysplastic syndromes (MDS): helps restore normal blood cell production and can reduce transfusion dependence. - Acute myeloid leukemia (AML): provides disease‑modifying activity that may achieve remission in patients unsuitable for intensive chemotherapy. - High‑risk MDS/AML overlap syndrome: offers a therapeutic option when conventional chemotherapy is not feasible.

Azacitidine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness. - Injection site reactions: erythema or pain at the subcutaneous site. - Cytopenias: decreased white blood cells, platelets, or red cells.

Serious or Rare Side Effects: - Tumor lysis syndrome: rapid cell breakdown leading to metabolic disturbances. - Severe infections: opportunistic or bacterial infections due to immunosuppression. - Hypersensitivity reactions: anaphylaxis or severe skin rash.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: regular CBCs to detect cytopenias. - Assess renal function: adjust use in patients with impaired clearance. - Evaluate hepatic function: monitor liver enzymes during treatment. - Avoid use in uncontrolled infection: active infections increase risk of severe complications. - Pregnancy considerations: the drug is contraindicated in pregnancy; discuss risks with women of childbearing potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Azacitidine can interact with other agents that affect bone marrow or immune function.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may cause profound cytopenias. - Live attenuated vaccines: increased risk of vaccine‑derived infection. - Strong immunosuppressants (e.g., high‑dose steroids): may exacerbate infection risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding. - Allopurinol: monitor for tumor lysis syndrome markers when used together.